Singapore, Mar 22, 2010: Matrix Corporate Capital and PharmaVentures announced the signing of a Memorandum of Understanding covering strategic transactions in the biotech, pharmaceutical and med tech sectors. The companies will work together to identify licensing, buyout, investment, IPO and consolidation opportunities which bring together both strategic expertise and capital from Europe's dedicated healthcare investors. The MoU joins two firms with synergistic transactional capabilities in the healthcare life sciences space.

Fintan Walton, Chief Executive of PharmaVentures said "For our clients our alliance with Matrix will create one of Europe's strongest teams in healthcare transactions and equity financing. Our clients have always demanded the best and a strong experienced healthcare team is essential to their own success. Matrix has excellent proven capabilities in corporate finance and we are delighted to have entered into this agreement."

Malcolm Le May, Chief Executive of Matrix Corporate Capital said, "We are delighted to team our skills with those of PharmaVentures. It has an excellent track record with some of the largest names in the pharmaceutical sector. Many of these companies now face unprecedented change in their business models, with the pursuit of greater efficiency driving buyouts; assets sales and licensing. Matrix has access to both private and public sector-specific capital across Europe which, with PharmaVentures' help, will allow us to create innovative transactions around these assets."